Remoxy ERTreatment for Pain
Remoxy NDA Accepted by the FDA
Remoxy New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011
CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire/ -- Durect Corporation today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for Remoxy by King Pharmaceuticals, Inc. and the PDUFA goal date is June 23, 2011.
Remoxy, based on Durect's Oradur technology, is an investigational drug that is a unique, controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. Approximately 50 million Americans suffer from persistent pain each year, according to the American Pain Foundation.
About Oradur Technology
Oradur is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of resisting common methods of prescription drug misuse and abuse compared to other controlled release dosage forms on the market today.
In December 2002, Durect licensed to Pain Therapeutics, Inc. (Nasdaq: PTIE) the right to develop and commercialize on a worldwide basis Remoxy and other oral sustained release drug candidates using the Oradur technology which incorporate four specified opioid compounds. Under the license agreement, Durect is reimbursed for formulation and other work performed under its agreement, and will receive additional payments if certain development and regulatory milestones are achieved with respect to the licensed drug candidates. In addition, if commercialized, Durect will receive royalties for Remoxy and the other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on Durect's supply of key excipients used in the manufacture of the licensed drug candidates. Pain Therapeutics sublicensed the commercialization rights of Remoxy and other licensed drug candidates to King Pharmaceuticals in November 2005. In October 2010, Pfizer Inc. (NYSE: PFE) announced that it had entered into a definitive merger agreement to acquire King. Should that transaction be completed, Pfizer would assume the development and commercialization rights and obligations to Remoxy and to the other licensed Oradur-based opioids.
About Durect Corporation
Durect is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy, Posidur Eladur, and Transdur-Sufentanil. Durect's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: Posidur, Saber, Oradur, Transdur, and Eladur are trademarks of Durect Corporation. Other referenced trademarks belong to their respective owners. Remoxy, Posidur, Eladur and Transdur-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
Durect Forward-Looking Statement
The statements in this press release regarding Remoxy, its potential attributes and statements related to the expected PDUFA review date goal by the FDA, the potential of FDA approving the Remoxy NDA, the potential royalty and other payments that may be received by Durect from Remoxy and other described products, and the potential acquisition of King by Pfizer are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the potential that the Remoxy NDA resubmission may not adequately address all of FDA's concerns, the potential that FDA may not grant regulatory approval of Remoxy, difficulties or delays in the development, testing, regulatory approval, production and commercialization of Remoxy, and unexpected adverse side-effects or inadequate therapeutic efficacy of Remoxy that could slow or prevent product approval or market acceptance, and that the Pfizer acquisition of King may not be completed. Further information regarding these and other risks is included in Durect's Form 10-Q dated November 4, 2010 under the heading "Risk Factors."
SOURCE Durect Corporation
CONTACT: Matthew J. Hogan, Chief Financial Officer of Durect Corporation, +1-408-777-4936
Web Site: http://www.durect.com
Posted: January 2011
- Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain - February 13, 2018
- Pain Therapeutics Receives Complete Response Letter for Remoxy ER - September 26, 2016
- FDA Accepts Remoxy NDA for Review - April 12, 2016
- Pain Therapeutics Resubmits Remoxy New Drug Application to the U.S. Food and Drug Administration - March 29, 2016
- Pfizer to Discontinue Agreement on Remoxy (oxycodone) Extended-Release Capsules CII - October 27, 2014
- FDA Complete Response Letter Received for Remoxy - June 24, 2011
- King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for Remoxy - December 27, 2010
- Pain Therapeutics Receives Complete Response Letter From FDA for Remoxy - December 11, 2008
- Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy - June 10, 2008